The Centers for Disease Control and Prevention (CDC) has refreshed its guidelines surrounding the vaccination of Respiratory Syncytial Virus (RSV) for older adults. This significant update primarily affects adults who are within the 60-74 age bracket with an elevated risk for RSV. In addition to this, all individuals aged 75 and over are now recommended to receive a single dose of the vaccine from leading pharmaceutical companies – GlaxoSmithKline (GSK), Pfizer, or Moderna.
As per these revised guidelines, it’s crucial to note that those who have already received a dose of the aforementioned vaccines are advised not to seek another dose. Such a step ensures an effective population-wide management of RSV risk, balancing both broad coverage and vaccine resources.
The information provided in this new guideline is strictly for noncommercial purposes and has been curated from www.aha.org, a resource granted access to AHA Institutional Members, along with their employees and associations at State, Regional, and Metro Hospital level unless specified otherwise. Hence, the American Health Association (AHA) does not hold ownership rights over third-party content incorporated into AHA produced materials. Any requests for reproduction of AHA content should be made directly to the organization for permission.
Source: https://www.aha.org/news/headline/2024-08-07-cdc-updates-rsv-vaccine-recommendations-older-adults